SelectQuote: Be Patient Until Growth Drivers Kick In

SelectQuote (SLQT) is deemed an undervalued buying opportunity despite a disappointing Q3 and recent volatility, trading at less than 6x forward adjusted EBITDA. The investment thesis centers on confirmed growth drivers for FY25 and beyond, specifically higher Medicare Advantage reimbursement rates, expanding SelectRx recurring revenue, and operational efficiencies. While risks from Medicare plan changes persist, they are largely priced in, prompting a recommendation to add shares on dips.

Analysis

The investment thesis for SelectQuote (SLQT) is presented as fundamentally bullish, positioning the company as an undervalued opportunity despite a recent disappointing Q3 and market volatility. The valuation is cited as a key attraction, with the stock trading at less than 6x forward adjusted EBITDA. The positive outlook for fiscal year 2025 and beyond is predicated on three specific catalysts: anticipated increases in Medicare Advantage reimbursement rates, growth in recurring revenue from its SelectRx pharmacy division, and ongoing operational improvements aimed at boosting efficiency and margins. While the analysis acknowledges risks stemming from potential changes in Medicare plans and the profitability timeline for SelectRx, it concludes that these factors are already reflected in the current stock price. It is important to note that the author has a disclosed beneficial long position in SLQT, which provides context for the strong recommendation to add shares on dips.

Key Decisions for Investors

• Given the valuation below 6x forward adjusted EBITDA, investors could consider the current share price an attractive entry point, aligning with the author's 'buy the dip' recommendation.
• Investors should closely track the execution of stated FY25 catalysts, specifically the revenue growth from the SelectRx unit and margin improvements from operational efficiencies.
• It is crucial to monitor any regulatory shifts in Medicare Advantage reimbursement policies, as this is a key macro driver for the thesis and a primary risk if trends reverse.
• The highly bullish stance should be weighed against the author's disclosed long position, warranting independent verification of the company's fundamental health and growth trajectory.